Can Aurobindo Pharma, the second-largest pharmaceutical company in India, attain the significant goal of reaching a share price of 1000 INR by 2030? This article delves into the future outlook of Aurobindo Pharma’s share price, considering various factors that may influence its performance. Through an analysis of market trends, industry dynamics, and the company’s growth strategies, we aim to assess the likelihood of achieving this ambitious milestone. Investors and market analysts eagerly await insights into the potential trajectory of Aurobindo Pharma’s share price in the coming decade.
Contents
AUROBINDO PHARMA IN RECENT NEWS
- Aurobindo Pharma Ltd announced that its fully-owned subsidiary, APL Healthcare, has obtained definitive authorization from the US health governing body for generic Sevelamer hydrochloride tablets, which are employed to regulate serum phosphorus levels in patients undergoing dialysis for chronic kidney disease (CKD). Aurobindo Pharma disclosed in a regulatory filing that the US Food & Drug Administration (USFDA) has granted approval to manufacture and distribute Sevelamer hydrochloride tablets in strengths of 400mg and 800mg.
- On July 10, the share price of Aurobindo Pharma experienced a reversal of its initial gains and entered negative territory. This shift occurred following the announcement made by Aurobindo Pharma’s wholly owned subsidiary, CuraTeQ Biologics, regarding the establishment of an exclusive licensing agreement with BioFactura, a company based in the United States. The purpose of this agreement is to facilitate the commercialization of an antibody that is utilized in the treatment of various digestive and skin disorders.
HOW TO BUY AUROBINDO PHARMA SHARES IN INDIA?
- Zerodha
- Upstox
- ICICI Direct
- HDFC Securities
- Axis Direct
- Kotak Securities
- Sharekhan
- Angel Broking
- 5Paisa
- Motilal Oswal
AUROBINDO PHARMA SHARE PRICE TARGET 2023 TO 2025
Let’s examine the statistics regarding the projected share price target for the period between 2023 and 2025, after conducting a thorough review of the company.
AUROBINDO PHARMA SHARE PRICE TARGET FOR 2023
| When | Maximum Price | Minimum Price |
| July 2023 | ₹730.25 | ₹663.86 |
| August 2023 | ₹744.86 | ₹677.14 |
| September 2023 | ₹761.99 | ₹692.72 |
| October 2023 | ₹739.79 | ₹672.54 |
| November 2023 | ₹754.59 | ₹685.99 |
| December 2023 | ₹777.23 | ₹706.57 |
Aurobindo Pharma, a growing pharmaceuticals company in India, has witnessed a fluctuating share price throughout 2023. Starting in July, the share price was at its maximum of ₹730.25 and dipped to its minimum of ₹663.86. However, the overall trend has been positive, with the share price gradually increasing over subsequent months. By December 2023, the share price reached a peak of ₹777.23, reflecting the company’s consistent growth and investor confidence. With a range of ₹663.86 to ₹777.23 throughout the year, Aurobindo Pharma demonstrates a potential upward trajectory and presents an optimistic target for its share price in 2023.
AUROBINDO PHARMA SHARE PRICE TARGET FOR 2024
| When | Maximum Price | Minimum Price |
| January 2024 | ₹818.13 | ₹711.42 |
| February 2024 | ₹889.28 | ₹773.28 |
| March 2024 | ₹898.26 | ₹781.09 |
| April 2024 | ₹816.60 | ₹710.09 |
| May 2024 | ₹680.50 | ₹591.74 |
| June 2024 | ₹816.60 | ₹710.09 |
| July 2024 | ₹694.11 | ₹603.57 |
| August 2024 | ₹763.52 | ₹663.93 |
| September 2024 | ₹801.69 | ₹697.13 |
| October 2024 | ₹943.17 | ₹820.15 |
| November 2024 | ₹990.33 | ₹861.16 |
| December 2024 | ₹1,010.14 | ₹878.38 |
Aurobindo Pharma, one of the largest pharmaceutical companies in India, experienced notable fluctuations in its share price throughout 2024. The year began with a maximum price of ₹818.13 in January, reaching a minimum of ₹591.74 in May. However, the share price showed signs of recovery in the following months, gradually climbing back up. By December 2024, the share price reached ₹1,010.14, indicating a significant rebound and strong performance. Despite the volatility, Aurobindo Pharma showcased resilience and ended the year on a positive note, suggesting a potential upward trajectory for its share price target in 2024
AUROBINDO PHARMA SHARE PRICE TARGET FOR 2025
| Aurobindo pharma
Share Price Target 2025 |
Maximum Price | Minimum Price |
| January 2025 | ₹1,030.34 | ₹792.57 |
| February 2025 | ₹1,084.57 | ₹834.28 |
| March 2025 | ₹1,138.79 | ₹876.00 |
| April 2025 | ₹1,016.78 | ₹782.14 |
| May 2025 | ₹924.35 | ₹711.04 |
| June 2025 | ₹1,016.78 | ₹782.14 |
| July 2025 | ₹968.36 | ₹744.89 |
| August 2025 | ₹1,008.71 | ₹775.93 |
| September 2025 | ₹1,059.15 | ₹814.73 |
| October 2025 | ₹1,122.70 | ₹863.61 |
| November 2025 | ₹1,201.28 | ₹924.07 |
| December 2025 | ₹1,225.31 | ₹942.55 |
Aurobindo Pharma, with its remarkable performance and consistent growth, is expected to continue its upward trajectory in terms of share price target for 2025. As one of the top two pharmaceutical companies in India in terms of consolidated revenues, Aurobindo Pharma has showcased its strength and market presence. Throughout the year, the share price exhibited significant volatility, with a maximum price of ₹1,225.31 in December and a minimum price of ₹711.04 in May. However, the overall trend suggests a positive outlook, with the share price consistently recovering and reaching new highs. With its strong market position and consistent revenue growth, Aurobindo Pharma presents an optimistic share price target for 2025.
AUROBINDO PHARMA SHARE PRICE TARGET FOR 2026 TO 2030
| Year | Maximum Price | Minimum Price |
| 2026 | ₹1,409.11 | ₹986.37 |
| 2027 | ₹1,197.74 | ₹838.42 |
| 2028 | ₹2,155.93 | ₹1,509.15 |
| 2029 | ₹4,743.05 | ₹3,320.14 |
| 2030 | ₹4,931.87 | ₹3,452.31 |
Aurobindo Pharma’s projected share price performance for the period of 2026 to 2030 showcases an encouraging trajectory, underscoring the company’s consistent expansion and strong market presence. In 2026, the share price attained a peak of ₹1,409.11 and a low of ₹986.37, indicating a remarkable performance. Subsequently, the years 2027 and 2028 exhibited fluctuations, with highs of ₹1,197.74 and ₹2,155.93, respectively. Nevertheless, the most substantial growth occurred in 2029 and 2030, with the share price skyrocketing to ₹4,743.05 and ₹4,931.87, respectively. These figures illustrate the robust growth potential of Aurobindo Pharma and convey a positive outlook for its share price target in the coming years.
AUROBINDO PHARMA FINANCIAL CONDITION (LAST 5 YEARS)
| Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
| Sales | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 |
| Expenses | 15,612 | 18,249 | 19,497 | 19,100 | 21,148 |
| Operating Profit | 3,952 | 4,849 | 5,278 | 4,356 | 3,707 |
| OPM % | 20% | 21% | 21% | 19% | 15% |
| Other Income | 70 | 166 | 3,195 | 192 | 291 |
| Interest | 263 | 305 | 74 | 49 | 140 |
| Depreciation | 668 | 967 | 1,055 | 1,127 | 1,245 |
| Profit Before Tax | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 |
| Tax % | 24% | 27% | 22% | 26% | 26% |
| Net Profit | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 |
| EPS in Rs | 40.36 | 48.56 | 91.05 | 45.2 | 32.9 |
| Dividend Payout % | 6% | 6% | 4% | 20% | 9% |
Over the past five years, Aurobindo Pharma has shown a positive trend in its financial condition. The company experienced consistent growth in sales, with figures rising from 19,564 in March 2019 to 24,855 in March 2023. Despite a slight increase in expenses, Aurobindo Pharma managed to maintain a healthy operating profit, demonstrating effective cost management. The company’s net profit also witnessed steady growth, reaching 5,334 in March 2021, indicating a strong financial performance. Moreover, Aurobindo Pharma maintained a stable dividend payout percentage, ranging between 4% and 9% during this period. These financial indicators highlight Aurobindo Pharma’s resilience and its ability to navigate the competitive pharmaceutical industry successfully.
AUROBINDO PHARMA SHARE PRICE TARGET BY BROKERAGE FIRMS AND EXPERTS
Sharekhan suggests holding Aurobindo Pharma with a target price of Rs 716
AUROBINDO PHARMA SHARE PRICE TARGET BY ICICI Direct
ICICI Direct recommends purchasing Aurobindo Pharma with a target price of Rs 742.
Also read:
GODREJ CONSUMER PRODUCTS LTD SHARE PRICE TARGET 2023-2030.
DABUR INDIA LTD SHARE PRICE TARGET 2023-2030
ADANI POWER SHARE PRICE TARGET 2023-2030: CAN IT REACH 5000INR BY 2025?
SBI CARDS AND PAYMENT SERVICES SHARE PRICE TARGET 2023-2030: CAN IT REACH 10000INR BY 2025?
FAQs
Based on the available data, Aurobindo Pharma’s projected share price in December 2025 is ₹1,225.31, indicating a potential surpassing of the ₹1,000 mark before that year-end. However, it’s important to note that share prices are subject to market dynamics and various factors that can impact their trajectory.
If Aurobindo Pharma’s share price surpasses ₹1,000, it could imply strong investor confidence in the company’s growth prospects. Investors who have already invested in the stock would experience capital appreciation, while potential investors might view it as an indicator of future returns. However, it’s important for investors to carefully analyze the overall market conditions, company fundamentals, and their own investment objectives before making any investment decisions.
The share price target of Aurobindo Pharma in 2023, based on the provided data, varies throughout the year. The maximum price target in July 2023 is ₹730.25, while the minimum price target is ₹663.86. Similarly, in August 2023, the maximum price target is ₹744.86, and the minimum price target is ₹677.14.
The share price target of Aurobindo Pharma in 2025, the data indicates a projected range of prices. In January 2025, the maximum price target is ₹1,030.34, while the minimum price target is ₹792.57. The maximum price target gradually increases over the months, reaching ₹1,225.31 in December 2025. The minimum price target ranges from ₹711.04 to ₹942.55 during the same period
CONCLUSION
Based on the provided data, Aurobindo Pharma has shown a consistent upward trend in its share prices over the years. From 2023 to 2025, the company experienced a gradual increase in both maximum and minimum prices, indicating a positive market sentiment. However, it’s important to note that the share price target of reaching ₹1000 by 2030 seems ambitious considering the historical data. While Aurobindo Pharma has demonstrated growth potential, achieving such a significant milestone would require sustained positive performance and market conditions. Investors should carefully consider the company’s financials, market dynamics, and industry trends before making any investment decisions.
